Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults

• Biological: 20vPnC
  
  20vPnC
• Biological: 13vPnC
  
  Pneumococcal conjugate vaccine
• Biological: PPSV23
  
  Pneumococcal polysaccharide vaccine
  Other Name: Pneumovax 23
• Other: Saline
  
  Placebo

• Experimental: 60 years and above 20vPnC/Saline
  
  20vPnC and saline
  Interventions:
  

  • Biological: 20vPnC
  • Other: Saline
• Active Comparator: 60 years and above 13vPnC/PPSV23
  
  13vPnC and PPSV23
  Interventions:
  

  • Biological: 13vPnC
  • Biological: PPSV23
• Experimental: 50 through 59 years of age 20vPnC
  
  20vPnC
  Intervention: Biological: 20vPnC
• Experimental: 18 through 49 years of age 20vPnC
  
  20vPnC
  Intervention: Biological: 20vPnC
• Active Comparator: 50 through 59 years of age 13vPnC
  
  13vPnC
  Intervention: Biological: 13vPnC
• Active Comparator: 18 through 49 years of age 13vPnC
  
  13vPnC
  Intervention: Biological: 13vPnC

Inclusion Criteria:

1. Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.
2. Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
3. Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.

Exclusion Criteria:

1. Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
2. History of microbiologically proven invasive disease caused by S pneumoniae.
3. Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
4. Pregnant female subjects or breastfeeding female subjects.